Immunogenicity of pembrolizumab in patients with advanced tumors

Overview of attention for article published in Journal for Immunotherapy of Cancer, August 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (85th percentile)
Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

policy: 1 policy source
twitter: 9 X users

patent: 3 patents

Citations

dimensions_citation: 30 Dimensions

Readers on

mendeley: 70 Mendeley

Summary Policy documents X Patents Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

pembrolizumab

Cited by Canadian Agency for Drugs and Technologies in Health on 22 Sep 2021

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.